AstraZeneca Pharma India Limited has been granted permission by the Central Drugs Standard Control Organisation to import pharmaceutical formulations of a new drug for sale or distribution in Form CT-20.

AstraZeneca Pharma import Olaparib (Lynparza)

The new drug is Olaparib film coated tablets of 100mg/150mg (Lynparza), which has an additional indication for use in combination with Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer. The permission received by AstraZeneca Pharma India Limited allows them to launch Olaparib film coated tablets in India, subject to any related statutory approvals.

HCL Technologies and Verizon Business Join Forces to Offer Managed Network Services Globally

Similar Posts